title: Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure.
abstract: Blood selenium has been shown to decline as breast cancer progresses and fluctuate with estrogen. The objective of this study was to determine the effect of estrogen depletion resulting from chemotherapy-induced ovarian failure on serum selenium and selenoproteins in stage I/II premenopausal breast cancer patients. Serum selenium, glutathione peroxidase (GPx) activity, and selenoprotein P (SelP) were measured and a dietary questionnaire was completed at baseline (before chemotherapy) and 6, 12, and 24 months after start of chemotherapy. Twelve months after the start of adjuvant chemotherapy 33 (75%) patients developed ovarian failure (OF) and 11 (25%) retained menstrual function (non-OF). Dietary selenium intake was 30-58% above the Recommended Dietary Allowance for both groups. By six months the mean estradiol (pg/ml) was lower in the OF group than in the non-OF group (32+/-5 versus 140+/-62 pg/ml, p=0.01) and this difference was maintained at 12 and 24 months. However, there was no differences in serum selenium, GPx activity, or SelP in the OF and non-OF groups at 6, 12, and 24 months. Selenium status in premenopausal breast cancer patients, as measured by serum selenium, GPx and SelP, was within the normal range before and following adjuvant chemotherapy, and was not affected by chemotherapy-induced ovarian failure.
authors.affiliation: Department of Human Nutrition, The Ohio State University, Columbus, OH 43210, USA.
authors.forename: Hollie A
authors.initials: HA
authors.lastname: Breedlove
authors.forename: Anne M
authors.initials: AM
authors.lastname: Smith
authors.forename: Raymond F
authors.initials: RF
authors.lastname: Burk
authors.forename: Kristina E
authors.initials: KE
authors.lastname: Hill
authors.forename: Charles L
authors.initials: CL
authors.lastname: Shapiro
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D019587:Dietary Supplements; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D009367:Neoplasm Staging; D017697:Premenopause; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced*; D011446:Prospective Studies; D012643:Selenium / Q000008:administration & dosage / Q000097:blood*; D051149:Selenoprotein P / Q000097:blood; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D051149:Selenoprotein P; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D005979:Glutathione Peroxidase; D012643:Selenium